The second group of mAbs developed for COVID-19 therapy includes anti-cytokine mAbs, which target the cytokine and chemokine storm, including IL-2, IL-6, IL-7, IL-17, G-CSF, GM-CSF, IP-10, MCP1, MIP1A, TNFα, IFN-ɣ, VEGF, and CCL2, described in patients with severe COVID-19 [71]. This evidence concerns the gene IFNA1 and COVID-19.